NFKB1 and cancer: Furthermore, the APOBEC network, which can promote cancer progression or metastasis or drug resistance under NF-κB signaling (Isozaki et al., 2023; Maruyama et al., 2016), may be downstream modulated by NF-κB/p53 signaling (Fig. 3G).